Patterns of rates of mortality in the Clinical Practice Research Datalink.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
03
2022
accepted:
06
07
2022
entrez:
4
8
2022
pubmed:
5
8
2022
medline:
9
8
2022
Statut:
epublish
Résumé
The Clinical Practice Research Datalink (CPRD) is a widely used data resource, representative in demographic profile, with accurate death recordings but it is unclear if mortality rates within CPRD GOLD are similar to rates in the general population. Rates may additionally be affected by selection bias caused by the requirement that a cohort have a minimum lookback window, i.e. observation time prior to start of at-risk follow-up. Standardised Mortality Ratios (SMRs) were calculated incorporating published population reference rates from the Office for National Statistics (ONS), using Poisson regression with rates in CPRD GOLD contrasted to ONS rates, stratified by age, calendar year and sex. An overall SMR was estimated along with SMRs presented for cohorts with different lookback windows (1, 2, 5, 10 years). SMRs were stratified by calendar year, length of follow-up and age group. Mortality rates in a random sample of 1 million CPRD GOLD patients were slightly lower than the national population [SMR = 0.980 95% confidence interval (CI) (0.973, 0.987)]. Cohorts with observational lookback had SMRs below one [1 year of lookback; SMR = 0.905 (0.898, 0.912), 2 years; SMR = 0.881 (0.874, 0.888), 5 years; SMR = 0.849 (0.841, 0.857), 10 years; SMR = 0.837 (0.827, 0.847)]. Mortality rates in the first two years after patient entry into CPRD were higher than the general population, while SMRs dropped below one thereafter. Mortality rates in CPRD, using simple entry requirements, are similar to rates seen in the English population. The requirement of at least a single year of lookback results in lower mortality rates compared to national estimates.
Identifiants
pubmed: 35925908
doi: 10.1371/journal.pone.0265709
pii: PONE-D-22-06497
pmc: PMC9352072
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0265709Subventions
Organisme : British Heart Foundation
ID : FS/19/11/34147
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: Michael Sweeting is a full-time employee of AstraZeneca
Références
J Public Health (Oxf). 2014 Dec;36(4):684-92
pubmed: 24323951
Alzheimers Dement (N Y). 2021 Aug 20;7(1):e12184
pubmed: 34458554
IARC Sci Publ. 1987;(82):1-406
pubmed: 3329634
Pharmacoepidemiol Drug Saf. 2016 Dec;25(12):1460-1464
pubmed: 27465256
Diabetes Ther. 2021 May;12(5):1299-1311
pubmed: 33721211
Rheumatology (Oxford). 2020 Oct 1;59(10):2898-2907
pubmed: 32097491
Pharmacoepidemiol Drug Saf. 2019 May;28(5):563-569
pubmed: 30908785
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
BMJ Open Gastroenterol. 2021 May;8(1):
pubmed: 34045238
Drugs Aging. 2021 Oct;38(10):911-920
pubmed: 34386936
Lancet. 2019 Sep 21;394(10203):1041-1054
pubmed: 31443926